MyCare - Patients: View your medical records securely online here.
Log in Learn More

GlaxoSmithKline LLC OMB112517: A Phase III, open label, randomized, multicenter trial of Ofatumumab maintenance treatment versus no further treatment in subjects with relapsed Chronic Lymphocytic Leukemia (CLL) who have responded to induction therapy.

IRB Number: GlaxoSmithKline LLC OMB112517
Status: Enrolling
Principal Name: Saad Jamshed, MD
Contact Name: Rachel O'Loughlin, RN
Phone: (585) 747-4555
Alternative Phone: (585) 922-9358